Chao A S, Chung C L, Wu C D, Chang S D, Cheng P J, Lin Y T, Soong Y K
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Kwei-Shan, Tao-Yuan, Taiwan.
Acta Obstet Gynecol Scand. 1999 May;78(5):393-7.
This study was to determine the incidence of chromosome abnormalities in Taiwanese women undergoing prenatal chromosome analysis after a second trimester Down syndrome screening by using maternal age and serum dual-marker testing (alpha-fetoprotein and free-beta unit human chorionic gonadotropin).
A total of 10,098 Taiwanese women with pregnancy between 15 and 23 weeks' gestation received second-trimester Down syndrome risk evaluation by dual-marker and maternal age specific risk testing in a single medical center. The study took 22 months. Ninety-seven percent of this study population was less than 34 years old. Ninety-six percent of our cases were screened between 15-20 weeks of gestation. This population was included only after a routine ultrasonography scan for correction of gestational age and exclusion of major structural anomalies. By using an algorithm to detect Down's syndrome, with a risk of 1:270 as a cut-off value, 816 patients were screen-positive for Down syndrome (screen-positive rate 8.0%). Karyotypes were reviewed for 670 (82.1%) mothers who received prenatal karyotype analysis.
Twelve cases of Down syndrome were identified in the screen positive group with an estimated detection rate of 67% (false positive rate 8%). Three cases of Down syndrome were detected in late trimester among the screen-negative group. Seven other fetal chromosome abnormalities were also found among the screen-positive pregnancy. In addition, seven cases were screen-positive for trisomy 18; all of these patients received amniocentesis and only one case was confirmed.
These findings indicate that this screening program combining alpha-fetoprotein (AFP), free beta human chorionic gonadotropin (free-hCG) and maternal age-specific would achieve a screening efficiency in Taiwanese populations as comparable to those obtained in Caucasian populations. Our results also suggest that approximately 3% of pregnancies with a positive dual marker and maternal age-specific screen results will have a chromosome abnormality despite having a normal routine ultrasound scan. Mothers with positive screening results should be made aware of the implications of a positive result.
本研究旨在通过孕妇年龄及血清双指标检测(甲胎蛋白和游离β-人绒毛膜促性腺激素),确定台湾地区孕中期唐氏综合征筛查后接受产前染色体分析的女性中染色体异常的发生率。
共有10098名妊娠15至23周的台湾地区女性在单一医疗中心接受了双指标及孕妇年龄特异性风险检测的孕中期唐氏综合征风险评估。该研究历时22个月。本研究人群中97%年龄小于34岁。96%的病例在妊娠15至20周期间接受筛查。该人群仅在进行常规超声扫描以校正孕周并排除主要结构异常后纳入。通过使用一种检测唐氏综合征的算法,以1:270的风险作为临界值,816例患者唐氏综合征筛查呈阳性(筛查阳性率8.0%)。对接受产前核型分析的670名(82.1%)母亲的核型进行了复查。
筛查阳性组中确诊12例唐氏综合征,估计检出率为67%(假阳性率8%)。筛查阴性组在孕晚期检测出3例唐氏综合征。在筛查阳性的妊娠中还发现了其他7例胎儿染色体异常。此外,7例18三体筛查呈阳性;所有这些患者均接受了羊水穿刺,仅1例得到确诊。
这些发现表明,这项结合甲胎蛋白(AFP)、游离β-人绒毛膜促性腺激素(free-hCG)和孕妇年龄特异性的筛查方案在台湾人群中可达到与白种人群相当的筛查效率。我们的结果还表明,尽管常规超声扫描正常,但约3%双指标及孕妇年龄特异性筛查结果呈阳性的妊娠会出现染色体异常。筛查结果呈阳性的母亲应了解阳性结果的意义。